EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Harnessing the Cross-Neutralisation Potential of Existing Antivenoms for Mitigating the Outcomes of Snakebite in Sub-Saharan Africa

Suyog Khochare iD, Anurag Jaglan, U Rashmi, Paulomi Dam, Kartik Sunagar iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25084213 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Suyog Khochare und 4 weiteren Autor:innen. Beteiligte Einrichtung: Evolutionary Venomics Lab, Centre for Ecological Sciences, Indian Institute of Science, Bangalore 560012, Karnataka, India. Hauptthemen laut MEDLINE: Antivenins, Snake Bites, Snake Venoms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust/DBT India Alliance, Hamish Ogston Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over 32,000 individuals succumb to snake envenoming in sub-Saharan Africa (sSA) annually. This results from several factors, including a lack of antivenom products capable of neutralising the venoms of diverse snake species in this region. Most manufacturers produce polyvalent antivenoms targeting 3 to 16 clinically important snake species in sSA. However, specific products are unavailable for many others, especially those with a restricted geographic distribution. While next-generation antivenoms, comprising a cocktail of broadly neutralising antibodies, may offer an effective solution to this problem, given the need for their clinical validation, recombinant antivenoms are far from being available to snakebite victims. One of the strategies that could immediately address this issue involves harnessing the cross-neutralisation potential of existing products. Therefore, we assessed the neutralisation potency of PANAF-Premium antivenom towards the venoms of 14 medically important snakes from 13 countries across sSA for which specific antivenom products are unavailable. Preclinical assays in a murine model of snake envenoming revealed that the venoms of most snake species under investigation were effectively neutralised by this antivenom. Thus, this finding highlights the potential use of PANAF-Premium antivenom in treating bites from diverse snakes across sSA and the utility of harnessing the cross-neutralisation potential of antivenoms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntiveninsSnake BitesSnake VenomsAnimalsAfrica South of the SaharaMiceSnakesAntibodies, NeutralizingHumansDisease Models, Animal

Stichwörter der Autor:innen

antivenomcross-neutralisation potencyin vitro bindingmedian lethal dosesnake venoms

Substanzen

AntiveninsSnake VenomsAntibodies, Neutralizing

Autor:innen und Institutionen

  • Evolutionary Venomics Lab, Centre for Ecological Sciences, Indian Institute of Science, Bangalore 560012, Karnataka, India.

ORCID-Profile: Suyog Khochare, Kartik Sunagar

Förderung

  • Wellcome Trust/DBT India Alliance
  • Hamish Ogston Foundation

Zitieren

APA

Khochare, S., Jaglan, A., Rashmi, U., Dam, P., & Sunagar, K. (2024). Harnessing the Cross-Neutralisation Potential of Existing Antivenoms for Mitigating the Outcomes of Snakebite in Sub-Saharan Africa. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25084213

Vancouver

Khochare S, Jaglan A, Rashmi U, Dam P, Sunagar K. Harnessing the Cross-Neutralisation Potential of Existing Antivenoms for Mitigating the Outcomes of Snakebite in Sub-Saharan Africa. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25084213

BibTeX
@article{Khochare2024,
  author = {Khochare, Suyog and Jaglan, Anurag and Rashmi, U and Dam, Paulomi and Sunagar, Kartik},
  title = {Harnessing the Cross-Neutralisation Potential of Existing Antivenoms for Mitigating the Outcomes of Snakebite in Sub-Saharan Africa},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25084213}
}
Kostenlos starten →